Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone

Free Abstracts

  Malignant Lymphoma

  Free Subscription


1 Biochem Biophys Res Commun
2 Blood
1 BMC Cancer
6 Br J Haematol
1 Cancer
1 Cancer Lett
1 Haematologica
4 Leuk Lymphoma
1 Mod Pathol

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Biochem Biophys Res Commun

  1. LI J, Qian C, Zhou Q, Li J, et al
    BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
    Biochem Biophys Res Commun. 2017 Jul 26. pii: S0006-291X(17)31498.
    PubMed     Text format     Abstract available


  2. CRUMP M, Neelapu SS, Farooq U, Van Den Neste E, et al
    Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
    Blood. 2017 Aug 3. pii: blood-2017-03-769620. doi: 10.1182/blood-2017-03-769620.
    PubMed     Text format     Abstract available

  3. ARCAINI L, Besson C, Frigeni M, Fontaine H, et al
    Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
    Blood. 2016 Sep 7. pii: blood-2016-05-714667.
    PubMed     Text format     Abstract available

    BMC Cancer

  4. LAI J, Xu P, Jiang X, Zhou S, et al
    Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report.
    BMC Cancer. 2017;17:507.
    PubMed     Text format     Abstract available

    Br J Haematol

  5. MAKAROVA O, Oschlies I, Muller S, Ruf S, et al
    Excellent outcome with limited treatment in paediatric patients with marginal zone lymphoma.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14868.
    PubMed     Text format    

  6. ZWAAN CM, Kowalczyk J, Schmitt C, Bielorai B, et al
    Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14874.
    PubMed     Text format     Abstract available

  7. FERRERI AJM, Cecchetti C, Kiesewetter B, Sassone M, et al
    Clarithromycin as a "repurposing drug" against MALT lymphoma.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14878.
    PubMed     Text format    

  8. HAGNER PR, Chiu H, Ortiz M, Apollonio B, et al
    Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14866.
    PubMed     Text format     Abstract available

  9. JAIN P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, et al
    Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14857.
    PubMed     Text format    

  10. KANATE AS, DiGilio A, Ahn KW, Al Malki M, et al
    Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14879.
    PubMed     Text format    


  11. YANIK EL, Shiels MS, Smith JM, Clarke CA, et al
    Contribution of solid organ transplant recipients to the pediatric non-hodgkin lymphoma burden in the United States.
    Cancer. 2017 Jul 31. doi: 10.1002/cncr.30923.
    PubMed     Text format     Abstract available

    Cancer Lett

  12. SOLE C, Larrea E, de Pinto G, Tellaexte M, et al
    miRNAs in B-cell lymphoma: Molecular mechanisms and biomarker potential.
    Cancer Lett. 2017 Jul 27. pii: S0304-3835(17)30456.
    PubMed     Text format     Abstract available


  13. BROCCOLI A, Pellegrini C, Di Rocco A, Puccini B, et al
    Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma.
    Haematologica. 2017 Aug 3. pii: haematol.2017.171355.
    PubMed     Text format     Abstract available

    Leuk Lymphoma

  14. KATSUSHIMA H, Fukuhara N, Konosu-Fukaya S, Himuro M, et al
    Does double-hit follicular lymphoma with translocations of MYC and BCL2 change the definition of transformation?
    Leuk Lymphoma. 2017 Aug 3:1-5. doi: 10.1080/10428194.2017.1357172.
    PubMed     Text format    

  15. ZHANG Y, Fan Y, Ying Z, Song Y, et al
    Can the SUVmax-liver-based interpretation improve prognostic accuracy of interim and posttreatment 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma?
    Leuk Lymphoma. 2017 Aug 3:1-10. doi: 10.1080/10428194.2017.1357171.
    PubMed     Text format     Abstract available

  16. JURCZAK W, Ramanathan S, Giri P, Romano A, et al
    Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2017 Aug 3:1-9. doi: 10.1080/10428194.2017.1357175.
    PubMed     Text format     Abstract available

  17. PAPIN A, Le Gouill S, Chiron D
    Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
    Leuk Lymphoma. 2017 Jul 31:1-9. doi: 10.1080/10428194.2017.1357177.
    PubMed     Text format     Abstract available

    Mod Pathol

  18. QUESADA AE, Medeiros LJ, Desai PA, Lin P, et al
    Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.
    Mod Pathol. 2017 Aug 4. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.